Healthcare ❯ Regulatory Affairs

FDA Approvals

Drug Development Drug Applications Drug Indications Medical Device Clearance Drug Safety Drug Approvals Clinical Trials Drug Approval Process Medical Devices Drug Pricing Brinsupri Drug Trials Drug Efficacy Drug Competition Drug Launches Metabolic Disorders Breakthrough Therapy Designation Drug Testing Veterinary Medicine Drug Submissions New Drug Formulations

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

Topline data could support an expedited FDA filing as a second confirmatory Phase 3 trial continues.

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

Evolus Posts Q1 Growth and Second Straight Positive Adjusted EBITDA, Reaffirms 2026 Outlook

ARCHIMED to Acquire Esperion for $3.16 a Share Plus CVR

Regeneron Tops Q1 Estimates as Dupixent and Libtayo Outpace Eylea

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

Boston Scientific Slumps to 52-Week Low After Watchman Trial Jitters and Downgrade

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

Repurposed Epilepsy Drug Cuts Sleep Apnea Events by Up to 47% in Phase II Trial

Ironwood Sees LINZESS Above $1.1 Billion in 2026 as FDA-Aligned STARS II Nears Launch

Dexcom Posts Q4 Beat, Launches 15‑Day G7, Reaffirms 2026 Outlook

BioMarin to Acquire Amicus for $4.8 Billion in Cash

FDA Adds Brain Tumor Warning to Two Depo‑Provera Injections

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

Regeneron Tops Q3 Forecasts on Dupixent Strength as Eylea HD Faces FDA Delay

Amgen Reports Repatha Cuts First-Event Risk in Primary-Prevention Trial

Merck Wins FDA Approval for Subcutaneous Keytruda as EU Panel Backs Infant RSV Preventive

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy